TARGINIQ Drug Patent Profile
✉ Email this page to a colleague
When do Targiniq patents expire, and when can generic versions of Targiniq launch?
Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are fifteen patents protecting this drug.
This drug has three hundred and five patent family members in forty-four countries.
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Targiniq
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 4, 2023. This may change due to patent challenges or generic licensing.
There have been twenty-six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for TARGINIQ
International Patents: | 305 |
US Patents: | 15 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Patent Applications: | 10 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TARGINIQ |
What excipients (inactive ingredients) are in TARGINIQ? | TARGINIQ excipients list |
DailyMed Link: | TARGINIQ at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TARGINIQ
Generic Entry Date for TARGINIQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for TARGINIQ
US Patents and Regulatory Information for TARGINIQ
TARGINIQ is protected by fifteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TARGINIQ is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TARGINIQ
Matrix for sustained, invariant and independent release of active compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Matrix for sustained, invariant and independent release of active compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Abuse-resistant controlled-release opioid dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
Oxycodone compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pharmaceutical preparation containing oxycodone and naloxone
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Pharmaceutical preparation containing oxycodone and naloxone
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TARGINIQ
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-001 | Jul 23, 2014 | See Plans and Pricing | See Plans and Pricing |
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | See Plans and Pricing | See Plans and Pricing |
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-001 | Jul 23, 2014 | See Plans and Pricing | See Plans and Pricing |
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-001 | Jul 23, 2014 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TARGINIQ
When does loss-of-exclusivity occur for TARGINIQ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Finland
Patent: 0070322
Estimated Expiration: See Plans and Pricing
Patent: 46
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TARGINIQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2002305559 | See Plans and Pricing | |
Malaysia | 154985 | OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE | See Plans and Pricing |
South Korea | 20130020962 | PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE | See Plans and Pricing |
Spain | 2415876 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TARGINIQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1685839 | CA 2013 00052 | Denmark | See Plans and Pricing | PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530 |
1685839 | 122013000082 | Germany | See Plans and Pricing | PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530 |
1685839 | 92292 | Luxembourg | See Plans and Pricing | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
1685839 | C300619 | Netherlands | See Plans and Pricing | PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |